Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

More documents

Recommendations

Info

88 Hyperbaric Oxygenation Therapy <strong>KCE</strong> Reports 74 Item Table 36. Overview of covered indications and fee-for-service Description Fee/Benefit 13015 HBOT, for treatment of Fee: $230.05 soft tissue radionecrosis or Benefit: 75%/85% chronic or recurring wounds where hypoxia can be demonstrated, 13020 for a period in the hyperbaric chamber of between 1 hour 30 minutes and 3 hours This item is funded on an interim basis and will cease on 31 October 2010. HBOT, for treatment of Fee: $233.70 decompression illness, Benefit: 75%/85% gas gangrene, air or gas embolism; diabetic wounds including diabetic gangrene and diabetic foot ulcers; necrotising soft tissue infections including necrotising fasciitis or Fournier's gangrene; or for the prevention and treatment of osteoradionecrosis, 13025 for a period in the hyperbaric chamber of between 1 hour 30 minutes and 3 hours HBOT for treatment of Fee: $104.50 decompression illness, Benefit: 75%/85% air or gas embolism, 13030 for a period in the hyperbaric chamber greater than 3 hours - per hour (or part of an hour) HBOT performed in a comprehensive hyperbaric medicine facility where Fee: $147.60 the medical practitioner is pressurised in the hyperbaric chamber for the purpose of providing continuous life saving emergency treatment, including any associated attendance - per hour (or part of an hour) Benefit: 75%/85% 6.7 Source: Medicare Benefits Schedule : http://www9.health.gov.au/mbs/search.cfm INTERNATIONAL COMPARISON: CONCLUSION There is no clear agreement on the use of HBOT when comparing the use of this therapy across countries. The acceptance of HBOT is mainly based on consensus for several indications. In proportion to the number of inhabitants and area, Belgium has a relatively large capacity of HBOT centres. With an area of about 30 500 km², Belgium has on average one HBOT centre per ~2 500 km². This is on average one centre per 3 700, 13 600, 15 500, 20 300 and 640 800 km² for the Netherlands, UK, US, France, and Australia respectively. In proportion to the number of inhabitants, only the US has a higher proportion of HBOT centres which are mainly monoplace chambers. This corresponds to about one centre per 875 000 inhabitants in Belgium. In contrast, there is on average one HBOT centre per 1.5, 1.7, 2.3, and 3.3 million inhabitants for the Netherlands, Australia, France, and the UK respectively. Key points • Internationally, reimbursement levels vary and reimbursed indications are mainly consensus based • Compared to surrounding countries, HBOT capacity is relatively high in Belgium
<strong>KCE</strong> Reports 74 Hyperbaric Oxygenation Therapy 89 7 CONCLUSIONS In this report we attempt to describe the history of hyperbaric oxygenation therapy (HBOT), the evidence for its use, the economic value of its application and cost for patients, hospitals and society, and also the current application of this technology in Belgium and in other countries. Despite the fact that HBOT has been in use for several decades, evidence on its effectiveness is remarkably poor. Although its use appears to be, under strict precautions, relatively save, it is important to evaluate this therapy carefully for several indications, to avoid overutilisation in indications where no benefit is likely, and to avoid underutilisation when potential benefits might be foregone because of lack of knowledge. Several indications have been accepted by medical scientific societies, but due to the paucity of properly randomised clinical study results, those acceptances are mainly based on a consensual decision making process rather than on an evidence based medicine approach. For a limited number of indications (mainly decompression illness) HBOT is likely to be important. For some indications there is limited evidence for benefits, for a few other indications HBOT is unlikely to be beneficial, and for several other indications HBOT might be beneficial but we just do not know. Therefore it is important to organise randomised clinical studies to sort out those uncertainties. In Table 37 we present an overview of the key results of this report.
Page 1 and 2:
Hyperbare Zuurstoftherapie: Rapid A
Page 3 and 4:
Hyperbare Zuurstoftherapie: Rapid A
Page 5 and 6:
KCE Reports 74A Hyperbare Zuurstoft
Page 7 and 8:
Page 9:
Page 12 and 13:
2 Hyperbaric Oxygenation Therapy KC
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
10 Hyperbaric Oxygenation Therapy K
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49: 38 Hyperbaric Oxygenation Therapy K
Page 100 and 101: KCE Reports 74 Hyperbaric Oxygenati
Page 130 and 131: Wettelijk depot : D/2008/10.273/13
Page 132: 38. Baarmoederhalskankerscreening e
show all

Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?